ObsEva Licenses Exclusive Rights to Kissei's Endometriosis Candidate; Agreement Amended; Agreement Terminated
Kissei Pharmaceutical Co. Ltd. granted ObsEva SA exclusive worldwide rights (excluding Asia) to its Phase II endometriosis candidate KLH2109, which ObsEva will develop as OBE2109 for that and other gynecologic conditions.
- Specialty Pharmaceuticals
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.